| 摘要 |
The present invention relates to a method for the treatment of benign prostatic hyperplasia in men (BPH). It is characterized by involving combined therapy with a 5α-reductase inhibitor, for example 17β- substituted 4-azasteroids, 17β-substituted non- azasteroids, 17β-acyl-3-carboxy-androst-3,5-dienes, benzoylaminophenoxy butanoic acid derivatives, cinnamoylamide derivatives, condensed benzo(thio)amides, aromatic 1,2-diethers or thioethers, aromatic alkanoic ortho-acylaminophenoxy acids, aromatic ortho- thioalkylacylaminophenoxyalkanoic acids or pharmaceutically acceptable salts or esters thereof, and particularly finasteride in combination with an α1- adrenergic receptor blocker, for example terazosin. The combination provides a therapy at molecular level for the underlying cause of the disease, as well as relief of symptoms. Pharmaceutical compositions that are useful in said method of treatment are also disclosed.
|
